Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen

Cancer

Volumn 104, Issue 2, 2005, Pages 345-353

  Tsimberidou, Apostolia Maria ^a   Younes, Anas ^a   Romaguera, Jorge ^a   Hagemeister, Fredrick B ^a   Rodriguez, Maria A ^a   Feng, Lei ^a   Ayala, Ana ^a   Smith, Terry L ^a   Cabanillas, Fernando ^a   McLaughlin, Peter ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CD4; Fludarabine; Immunoglobulins; Immunosuppression; Infections; Prognostic factors

Indexed keywords

ALPHA2B INTERFERON; ANTIBIOTIC AGENT; DEXAMETHASONE; FLUDARABINE; IMMUNOGLOBULIN G; MITOXANTRONE; PURINE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW SUPPRESSION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTIOUS COMPLICATION; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTOSIS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOSUPPRESSION; INFECTION; INTERFERONS; LYMPHOMA; MALE; MIDDLE AGED; MITOXANTRONE; NEUTROPENIA; VIDARABINE;

EID: 22244461829     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21151     Document Type: Article

References (33)

1. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:2431-2448.
2. Morrison VA. The infectious complications of chronic lymphocytic leukemia. Semin Oncol. 1998;25:98-106.
3. Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in patients with relapsed leukemia. Leukemia. 1987;1:638-643.
4. Boldt DH, Von Hoff DD, Kuhn JG, Hersh M. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2- fluoroadenine-5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res. 1984;44:4661-4666.
5. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999;5:444-447.
6. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19-25.
7. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165-1171.
8. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet, 1996;347:1432-1438.
9. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.[comment]. N Engl J Med. 2000;343:1750-1757.
10. Tsimberidou AM, Keating MJ, Giles FJ, et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer. 2004;100:2583-2591.
11. McLaughlin P, Hagemeister FB, Swan F Jr., et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994;12:575-579.
12. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262-1268.
13. Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with Stage IV indolent lymphoma. Blood. 2002;100:4351-4357.
14. Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up- a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000;18:987-994.
15. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
16. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71-75.
17. Hochster H, Weller E, Kuzel T, Frankel S, Horning S. Increased mortality associated with higher dose cyclophosphamide plus fludarabine in advanced stage indolent lymphoma patients treated on E1496, an ECOG and CALGB study [abstract]. Proc Am Soc Clin Oncol. 2002;21:282a.
18. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc. 2000;75:1039-1054.
19. Cancer Therapy Evaluation Program, National Cancer Institute. The revised Common Toxicity Criteria, version 2.0 [CTEP website]. Available from URL: http://ctep.info.nih. gov [accessed May 20, 2005].
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group [review]. J Clin Oncol. 1999;17:1244.
21. Robertson LE, O'Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995;9:1444-1449.
22. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993;82:1695-1700.
23. Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993;81:2878-2884.
24. Lazzarino M, Orlandi E, Baldanti F, et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol. 1999;107:877-882.
25. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559-566.
26. Byrd JC, Hargis JB, Rester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995;49:135-142.
27. Wacker P, Ozsahin H, Groll AH, Gervaix A, Reinhard L, Humbert J. Trimethoprim-sulfamethoxazole salvage for refractory listeriosis during maintenance chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2000;22:340-343.
28. Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol. 2000;11:363-365.
29. Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol. 2001;12:1455-1460.
30. Emmanouilides C, Rosen P, Rasti S, Territo M, Kunkel L. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a Phase II trial. Hematol Oncol. 1998;16:107-116.
31. Ahuja SS, Reddick RL, Sato N, et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol. 1999;163:3890-3897.
32. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
33. Keren DF, McCoy JP, Carey JL. Reference range appendix. In: Karen D, editor. Flow cytometry in clinical diagnosis, 3rd ed. Chicago: American Society of Clinical Pathology Press, 2001:703.